Subgroup Analyses of a Phase 3 Study in Patients with Myelodysplastic Syndromes Failing HMA Treatment: Identification of a Homogeneous Population Who Benefit from Rigosertib Therapy

In-depth analysis of ONTIME, and found that patients with the worst prognosis at entry, and thus with the greatest unmet medical need, appeared to benefit most from rigosertib treatment; namely, those with Primary AZA Failure, Very High Risk (VHR)-Revised International Prognostic Scoring System (IPSS-R), and monosomy 7 (Poster, Onconova, JUN 15, 2015, View Source;fileid=835336&filekey=758FA9A5-D91E-46AA-BC88-6A3B6C7CC728&filename=Gaidano_EHA_2015_ONTIME_subgroups.pdf [SID:1234507264]). The analyzed duration of prior hypomethylating agent (HMA) treatment inversely correlated with survival benefit.
Based on these results, a new randomized prospective controlled study in this high-risk MDS patient population comparing rigosertib to physician’s choice will be conducted to confirm these important observations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!